MedAvail, Inc (MDVL)
| Market Cap | 373.77M |
| Revenue (ttm) | 13.97M |
| Net Income (ttm) | -26.81M |
| Shares Out | 5.72M |
| EPS (ttm) | -4.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 12 |
| Last Price | $11.50 |
| Previous Close | $12.00 |
| Change ($) | -0.50 |
| Change (%) | -4.17% |
| Day's Open | 11.66 |
| Day's Range | 11.18 - 11.86 |
| Day's Volume | 29,520 |
| 52-Week Range | 0.84 - 20.79 |
MISSISSAUGA, Ontario & PHOENIX--(BUSINESS WIRE)--MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”) a technology-enabled pharmacy company, today announced it will report financial results for the first...
MISSISSAUGA, Ontario & PHOENIX--(BUSINESS WIRE)--MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”), a technology-enabled retail pharmacy company, today announced that a health system in North Texas ha...
MISSISSAUGA, Ontario & PHOENIX--(BUSINESS WIRE)--MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”) a technology-enabled pharmacy company, today reported financial results for the three months and full...
MISSISSAUGA, Ontario & PHOENIX--(BUSINESS WIRE)--MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”) a technology-enabled pharmacy company, today announced it will report financial results for the fourt...
MISSISSAUGA, Ontario & PHOENIX--(BUSINESS WIRE)--MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”), a technology-enabled retail pharmacy company, today announced that TMCOne has continued to expand it...
MISSISSAUGA, Ontario & PHOENIX--(BUSINESS WIRE)--MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”) a technology-enabled retail pharmacy company, today announced that the company will be participating ...
MISSISSAUGA, Ontario & PHOENIX--(BUSINESS WIRE)--MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”) a technology-enabled pharmacy company, today announced preliminary financial and operational results ...
MISSISSAUGA, Ontario & PHOENIX--(BUSINESS WIRE)--MedAvail, Inc. (“MedAvail”), a technology-enabled retail pharmacy company driving best in class medication adherence by embedding its pharmacy services d...
MISSISSAUGA, Ontario & PHOENIX--(BUSINESS WIRE)--MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”) a technology-enabled retail pharmacy company driving best in class medication adherence by embedding ...
MISSISSAUGA, Ontario & PHOENIX--(BUSINESS WIRE)--MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”), a technology-enabled retail pharmacy company driving best in class medication adherence by embedding...
MISSISSAUGA, Ontario & PHOENIX--(BUSINESS WIRE)--MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”) a technology-enabled retail pharmacy company driving best in class medication adherence by embedding ...
MISSISSAUGA, Ontario & PHOENIX--(BUSINESS WIRE)--MedAvail Holdings, Inc. (“MedAvail”), a leading technology-enabled pharmacy organization that embeds automated pharmacy services directly into clinics an...
MISSISSAUGA, Ontario & CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--MedAvail, Inc. (“MedAvail”), a leading technology-enabled pharmacy organization that embeds pharmacy services directly into clinics and other ...
CEDAR KNOLLS, N.J., Nov. 12, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS) As previously announced, on June 30, 2020, MYOS RENS Technology, Inc., a Nevada corpo...
CEDAR KNOLLS, N.J., Nov. 6, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive ...
NEW YORK, July 7, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of MYOS RENS Technology Inc. ("MYOS" or the...
CEDAR KNOLLS, N.J., July 7, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprieta...
NEW YORK, July 2, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between MYOS RENS Technology Inc. (NASDAQ: MYOS) and MedAvail, Inc. is fai...
New York, New York--(Newsfile Corp. - July 2, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased MYOS RENS Technology Inc. (NASDAQ: MYOS) ...
Shares of nutrition company MYOS Corporation (NASDAQ: MYOS) were more than doubling Wednesday.
CEDAR KNOLLS, N.J. and MISSISSAUGA, Ontario, June 30, 2020 /PRNewswire/ -- MYOS RENS Technology, Inc. ("MYOS") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary ...
CEDAR KNOLLS, N.J., May 14, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps b...
MYOS RENS Technology's (MYOS) CEO Joseph Mannello on Q1 2020 Results - Earnings Call Transcript
MYOS RENS Technology Inc (MYOS) CEO Joseph Mannello on Q4 2019 Results - Earnings Call Transcript
MYOS RENS Technology Inc (MYOS) CEO Joseph Mannello on Q3 2019 Results - Earnings Call Transcript
MYOS RENS Technology Inc. (MYOS) CEO Joseph Mannello on Q1 2019 Results - Earnings Call Transcript
MYOS RENS Technology Inc. (MYOS) CEO Joseph Mannello on Q4 2018 Results - Earnings Call Transcript
About MDVL
MedAvail Holdings, Inc. operates as a technology enabled pharmacy company that embeds automated pharmacy services directly into clinics and other points of care through its proprietary technology. The company provides turnkey services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations. It also operates SpotRx, a telehealth platform that delivers remote pharmacist consultations through an on-site dispensing kiosk, supplemented with home delivery. MedAvail Holdings, Inc. is based in Mississau... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | |
| CEO Joseph Mannello | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol MDVL |
Financial Performance
In 2020, MedAvail's revenue was $13.97 million, an increase of 270.41% compared to the previous year's $3.77 million. Losses were -$26.81 million, 24.5% more than in 2019.
Analyst Forecasts
The average 12-month stock price forecast for MedAvail is 20.00, which is an increase of 73.91% from the latest price.